Windtree Therapeutics (WINT) Competitors $0.01 0.00 (-11.88%) As of 05/22/2026 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock WINT vs. IOBT, ADIL, INDP, VIVS, and GLMDShould you buy Windtree Therapeutics stock or one of its competitors? MarketBeat compares Windtree Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Windtree Therapeutics include IO Biotech (IOBT), Adial Pharmaceuticals (ADIL), Indaptus Therapeutics (INDP), VivoSim Labs (VIVS), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry. WINT vs. IOBTWINT vs. ADILWINT vs. INDPWINT vs. VIVSWINT vs. GLMDHow does Windtree Therapeutics compare to IO Biotech?IO Biotech (NASDAQ:IOBT) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Does the media refer more to IOBT or WINT? In the previous week, IO Biotech's average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score. Company Overall Sentiment IO Biotech Neutral Windtree Therapeutics Neutral Which has more risk & volatility, IOBT or WINT? IO Biotech has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Do institutionals & insiders hold more shares of IOBT or WINT? 54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 2.3% of IO Biotech shares are owned by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, IOBT or WINT? IO Biotech is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$95.49M-$1.35N/AWindtree TherapeuticsN/AN/A-$1.79M-$8.77N/A Is IOBT or WINT more profitable? Windtree Therapeutics' return on equity of -207.34% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -517.22% -200.69% Windtree Therapeutics N/A -207.34%-50.19% Do analysts prefer IOBT or WINT? IO Biotech currently has a consensus target price of $3.50, suggesting a potential upside of 7,191.67%. Given IO Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe IO Biotech is more favorable than Windtree Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIO Biotech and Windtree Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.How does Windtree Therapeutics compare to Adial Pharmaceuticals?Windtree Therapeutics (NASDAQ:WINT) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do analysts prefer WINT or ADIL? Adial Pharmaceuticals has a consensus target price of $22.75, suggesting a potential upside of 993.75%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Windtree Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is WINT or ADIL more profitable? Adial Pharmaceuticals' return on equity of -162.82% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Windtree TherapeuticsN/A -207.34% -50.19% Adial Pharmaceuticals N/A -162.82%-127.58% Which has more volatility & risk, WINT or ADIL? Windtree Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Do insiders & institutionals believe in WINT or ADIL? 29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, WINT or ADIL? Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWindtree TherapeuticsN/AN/A-$1.79M-$8.77N/AAdial PharmaceuticalsN/AN/A-$7.98M-$7.98N/A Does the media favor WINT or ADIL? In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score. Company Overall Sentiment Windtree Therapeutics Neutral Adial Pharmaceuticals Neutral SummaryAdial Pharmaceuticals beats Windtree Therapeutics on 7 of the 12 factors compared between the two stocks.How does Windtree Therapeutics compare to Indaptus Therapeutics?Windtree Therapeutics (NASDAQ:WINT) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk. Is WINT or INDP more profitable? Windtree Therapeutics' return on equity of -207.34% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Windtree TherapeuticsN/A -207.34% -50.19% Indaptus Therapeutics N/A -1,030.07%-299.69% Do analysts prefer WINT or INDP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher valuation & earnings, WINT or INDP? Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWindtree TherapeuticsN/AN/A-$1.79M-$8.77N/AIndaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A Does the media favor WINT or INDP? In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score. Company Overall Sentiment Windtree Therapeutics Neutral Indaptus Therapeutics Neutral Do institutionals and insiders believe in WINT or INDP? 29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, WINT or INDP? Windtree Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. SummaryWindtree Therapeutics beats Indaptus Therapeutics on 7 of the 9 factors compared between the two stocks.How does Windtree Therapeutics compare to VivoSim Labs?Windtree Therapeutics (NASDAQ:WINT) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Which has better earnings and valuation, WINT or VIVS? Windtree Therapeutics has higher earnings, but lower revenue than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWindtree TherapeuticsN/AN/A-$1.79M-$8.77N/AVivoSim Labs$142K24.98-$2.48M-$3.15N/A Which has more volatility & risk, WINT or VIVS? Windtree Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Do analysts recommend WINT or VIVS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is WINT or VIVS more profitable? Windtree Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Windtree TherapeuticsN/A -207.34% -50.19% VivoSim Labs -861.27%-15.51%-11.31% Do insiders and institutionals have more ownership in WINT or VIVS? 29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor WINT or VIVS? In the previous week, VivoSim Labs had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for VivoSim Labs and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score. Company Overall Sentiment Windtree Therapeutics Neutral VivoSim Labs Neutral SummaryVivoSim Labs beats Windtree Therapeutics on 7 of the 12 factors compared between the two stocks.How does Windtree Therapeutics compare to Galmed Pharmaceuticals?Windtree Therapeutics (NASDAQ:WINT) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Is WINT or GLMD more profitable? Galmed Pharmaceuticals' return on equity of -29.43% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Windtree TherapeuticsN/A -207.34% -50.19% Galmed Pharmaceuticals N/A -29.43%-26.00% Do insiders and institutionals have more ownership in WINT or GLMD? 29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer WINT or GLMD? In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Windtree Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Windtree Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Windtree Therapeutics Neutral Galmed Pharmaceuticals Positive Do analysts rate WINT or GLMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable valuation & earnings, WINT or GLMD? Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWindtree TherapeuticsN/AN/A-$1.79M-$8.77N/AGalmed PharmaceuticalsN/AN/A-$10.31M-$1.24N/A Which has more risk and volatility, WINT or GLMD? Windtree Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. SummaryGalmed Pharmaceuticals beats Windtree Therapeutics on 8 of the 11 factors compared between the two stocks. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition ExportMetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$634K$3.37B$6.40B$12.31BDividend YieldN/A2.28%2.76%5.31%P/E Ratio0.0018.9321.0025.66Price / SalesN/A325.37556.1383.75Price / CashN/A131.8944.5756.72Price / Book0.017.1110.377.14Net Income-$1.79M$24.45M$3.56B$335.72M7 Day PerformanceN/A3.32%5.10%3.03%1 Month PerformanceN/A2.13%3.58%2.88%1 Year PerformanceN/A63.43%34.18%35.20% Windtree Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree TherapeuticsN/A$0.01-11.9%N/A-98.1%$634KN/AN/A30Gap DownIOBTIO BiotechN/A$0.05flat$3.50+7,191.7%N/A$3.45MN/AN/A30ADILAdial Pharmaceuticals1.5297 of 5 stars$2.06+28.0%$22.75+1,004.4%-88.4%$3.45MN/AN/A20Positive NewsHigh Trading VolumeINDPIndaptus Therapeutics0.3149 of 5 stars$1.33-12.5%N/A-88.5%$3.41MN/AN/A6Earnings ReportGap UpVIVSVivoSim Labs0.3122 of 5 stars$1.29+1.6%N/AN/A$3.31M$140KN/A20 Related Companies and Tools Related Companies IOBT Competitors ADIL Competitors INDP Competitors VIVS Competitors GLMD Competitors ENSC Competitors VCNX Competitors ALBT Competitors CASI Competitors SBFM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
